Compare Carvana Co (CVNA) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs State Street SPDR S&P Biotech ETF — how do they compare? Carvana Co trades at $63.72 (market cap $69.55B), while State Street SPDR S&P Biotech ETF trades at $153.72 (market cap $10.11B). The key difference: Carvana Co is far larger — about 6.9× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| CVNA | XBI | |
|---|---|---|
Market Cap | $69.55B | $10.11B |
Volume | 7,671,750 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $95.69 | $169.55 |
52-Week Low | $56.27 | $104.99 |
Typical Hold Time | 28 Days | 38 Days |
Enterprise Value | $72.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $64.26, up 2.39% on the day, showing resilience amid a bearish technical signal. The company reported strong revenue growth to $20.32B in 2025 with net income of $1.41B, and has beaten EPS estimates for three consecutive quarters. Positive analyst sentiment is highlighted by a consensus price target of $84.07, though technical indicators suggest near-term caution with key support at $61.
Outlook remains positive due to robust earnings beats and expansion initiatives, but risks include high debt levels and competitive pressures. The stock offers growth potential if operational execution continues, yet investors should monitor cash flow sustainability and market volatility.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
